CORONA2,200.00

CORONA Remedies Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersERISMANKINDAPLLTDALIVUSAKUMSAGARWALEYEHCGADVENZYMESMcap ₹13,455 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations361.1342.4353.1422.4
Other Income2.32.24.13.2
Total Income363.4344.7357.2425.6
Expenses
+ Cost of Materials Consumed25.924.827.732.7
+ Purchases of Stock-in-Trade28.141.246.357.2
+ Changes in Inventories14.6-5.7-7.8-12.3
+ Employee Benefit Expense103.095.9106.6122.1
+ Finance Costs1.91.71.42.7
+ Depreciation & Amortisation9.29.510.313.2
+ Other Expenses111.0103.1118.2129.7
Total Expenses293.8270.4302.7345.2
EBITDA78.583.262.093.1
EBIT69.373.751.779.9
Profit
PBT before Exceptional Items69.674.354.580.4
+ Exceptional Items0.0-19.10.30.0
Pretax Income69.655.254.780.4
+ Current Tax15.917.14.218.4
+ Deferred Tax1.6-3.25.21.9
Tax Expense17.513.99.420.3
+ Share of Associates & JVs0.20.00.00.0
Net Income52.341.345.360.1
+ Net Income — Continuing Ops52.241.345.360.1
+ Other Comprehensive Income0.3-0.10.7-0.3
Total Comprehensive Income52.641.246.059.8
Net Income to Common52.341.345.360.1
Per Share
Basic EPS8.556.757.419.83
Diluted EPS8.556.757.419.83
Other Comprehensive Income — detail
+ Other Comprehensive Income0.3-0.10.7-0.3
+ Items NOT to be Reclassified to P&L0.4
+ Tax on Items NOT to be Reclassified0.10.1-0.70.3
Comprehensive Income — Owners of Parent52.6-0.10.7-0.3
Per Share — as-filed variants
Basic EPS — Continuing Operations8.556.757.419.83
Diluted EPS — Continuing Operations8.556.757.419.83
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit292.5282.2286.9344.9
Gross Margin %80.9982.4081.2481.65
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)69.674.354.580.4
− Exceptional Items (reconciliation)0.0-19.10.30.0
Net Income Adj (tax-effected)52.355.545.160.1
EPS Adj8.559.087.379.83
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.00
Paid Up Equity Capital61.261.261.261.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.